[非瘤基因成的转移性非小细胞肺癌的第一线治疗]
1Centre Léon-Bérard, 28 rue Laennec, 69008 Lyon, France.
Bulletin du cancer
|March 28, 2025
概括
抗PD-(L) 1免疫疗法是高级非小细胞肺癌的关键治疗方法. 根据PD-L1水平和患者因素个性化治疗改善了结果,尽管耐药性仍然是一个挑战.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 肺部病理学 肺部病理学
背景情况:
- 反编程死亡配体1 (PD-L1) 免疫疗法是IV期非瘤基因成非小细胞肺癌 (NSCLC) 的标准.
- PD-L1表达水平预测了对抗PD-L1治疗的反应,>50%的表达允许无化疗选择.
研究的目的:
- 审查抗PD-(L) 1免疫疗法在第四阶段NSCLC的第一线治疗中的疗效.
- 讨论治疗个性化策略和改善治疗结果的未来方向.
主要方法:
- 在NSCLC中对抗PD-(L) 1免疫疗法的I期和III期临床研究的审查.
- 分析影响治疗反应和耐药性的因素.
主要成果:
- 在PD-L1>50%的NSCLC中使用Pembrolizumab单疗法显示中位生存时间为26个月,5年生存时间为32%.
- 抗PD-(L) 1和化疗的结合可以使PD-L1水平的5年生存率从10%增加到18%.
- 双重免疫疗法 (抗CTLA-4和抗PD-L) 显示出潜力,特别是在PD-L1阴性瘤中.
结论:
- 考虑到患者和瘤因素的治疗个性化对于优化NSCLC免疫治疗至关重要.
- 需要进一步的研究来克服免疫疗法耐药性,并确定最佳的治疗持续时间.
关键词:
抗PD-1病毒的使用.抗PD-L1的 抗PD-L1 的支气管癌没有小细胞化疗 化疗是一种化学疗法.化学疗法是一种化学疗法.转化状态的转化状态.非小细胞肺癌是非小细胞肺癌.第四阶段IV阶段治疗 治疗 治疗治疗方法 治疗方法更多相关视频
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.8K
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
8.5K
相关概念视频
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Treatment Resistent Cancers
1.4K
No description available
1.4K
Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
